

What is claimed is:

1. An antisense oligonucleotide 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding PPAR-delta, wherein said antisense oligonucleotide specifically
5 hybridizes with said nucleic acid molecule encoding PPAR-delta and has a sequence comprising SEQ ID NO: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 71, 72, 73, 74, 75, 76,
10 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 95 or 96.
2. The antisense oligonucleotide of claim 1 which comprises at least one modified internucleoside linkage.
3. The antisense oligonucleotide of claim 2 wherein
15 the modified internucleoside linkage is a phosphorothioate linkage.
4. The antisense oligonucleotide of claim 1 which comprises at least one modified sugar moiety.
5. The antisense oligonucleotide of claim 4 wherein
20 the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
6. The antisense oligonucleotide of claim 1 which comprises at least one modified nucleobase.
7. The antisense oligonucleotide of claim 6 wherein
25 the modified nucleobase is a 5-methylcytosine.
8. The antisense oligonucleotide of claim 1 which is a chimeric oligonucleotide.
9. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion
30 of a preferred target region on a nucleic acid molecule encoding PPAR-delta.
10. A composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 35 11. The composition of claim 10 further comprising a colloidal dispersion system.